Kidney Disease Clinical Trials

A listing of Kidney Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 304 clinical trials
A Multicenter Non-inferiority Randomized Trial Comparing Cloxacillin Versus Cefazolin Efficacy for the Treatment of Bacteremia Caused by Methicillin-susceptible Staphylococcus Aureus (MSSA) (CLOCEBA)

"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%. Anti-staphylococcal penicillins (APs) such as oxacillin or cloxacillin are recommended as first-line agents. With the exception of first-generation cephalosporin (1GC) such as cefazolin, no alternative has yet proven …

  • 24 Oct, 2022
  • 1 location
Evaluation of a New Bladder Health Mobile Application in Pregnancy (BHmApp)

Millions of women experience involuntary loss of urine called urinary incontinence (UI). UI can be slightly bothersome or totally debilitating. Women experience UI twice as often as men. Urinary incontinence can also be a persistent condition caused by underlying physical problems or changes, including pregnancy and childbirth. UI symptom severity …

pelvic floor muscle training
Accepts healthy volunteers
  • 16 Oct, 2022
  • 1 location
Young Adults With Early-onset Obesity Treated With Semaglutide -The RESETTLE Study (RESETTLE)

Introduction: Obesity prevalence is particularly pronounced among adolescents. Currently available treatment options consists of structured lifestyle interventions. However, 25 % of adolescents do not respond to lifestyle treatment, why new effective treatment strategies are needed. Therefore, the aim of this study is to investigate the effect of lifestyle interventions combined …

Accepts healthy volunteers
  • 22 Oct, 2022
  • 1 location
Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive

renal function
  • 04 Oct, 2022
  • 119 locations
A Phase 2b Diabetic Kidney Disease Study

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

diabetic nephropathy
  • 04 Oct, 2022
  • 75 locations
PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PRECIDENTD)

total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney

  • 15 Oct, 2022
  • 1 location
Improving Medical Decision Making for Older Patients With End Stage Renal Disease (VIDEO-KD)

The overall objective of this study is to reduce the burden of chronic kidney disease (CKD) and its consequences for an aging U.S. population. To accomplish this, the investigators propose to

  • 16 Oct, 2022
  • 8 locations
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

monoclonal antibodies
kidney biopsy
  • 07 Oct, 2022
  • 12 locations
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States (GUARDD-US)

The primary aim is to determine the effect of participant and provider knowledge of a positive APOL1 status and accompanying guideline based clinical decision support (CDS) on blood pressure management on change in systolic blood pressure (SBP) from baseline to 3 months after randomization among the APOL1 positive participants. Secondary …

antihypertensive drugs
apolipoprotein l1
hemoglobin a1c
  • 12 Oct, 2022
  • 10 locations
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

cardiac event (MACE) in people with Chronic Kidney Disease (CKD) stages 4 or 5 or dialysis-dependent End Stage Kidney Disease (ESKD), and elevated cardiovascular (CV) risk, whilst maintaining an

  • 04 Oct, 2022
  • 34 locations